US equities |
MU $1,097.39 ▲+0.00% NVDA $230.86 ▲+0.00% SNDK $1,787.69 ▲+0.00% STX $945.57 ▲+0.00% WDC $462.56 ▲+0.00% NKE $35.15 ▲+0.00% MSTR $160.50 ▲+0.00% INTC $120.00 ▲+0.00%
FinancialContent

Articles published by Replimune, Inc.

News headline image
Replimune Announces TUDRIQEV™ Now Available in the U.S. for Advanced Melanoma
From Replimune, Inc.
Via GlobeNewswire
Tickers REPL
News headline image
Replimune to Present at the Cantor Global Healthcare Conference 2026
From Replimune, Inc.
Via GlobeNewswire
Tickers REPL
News headline image
Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Replimune, Inc.
Via GlobeNewswire
Tickers REPL
News headline image
Replimune Reports Fiscal First Quarter 2027 Financial Results and Provides Corporate Update
From Replimune, Inc.
Via GlobeNewswire
Tickers REPL
News headline image
Replimune Announces Pricing of $150 Million Underwritten Offering
From Replimune, Inc.
Via GlobeNewswire
Tickers REPL
News headline image
Replimune Announces FDA Accelerated Approval of TUDRIQEVTM in Combination with Nivolumab for Unresectable Advanced Cutaneous Melanoma After Progression on an anti-PD-1 Based Regimen
From Replimune, Inc.
Via GlobeNewswire
Tickers REPL
News headline image
Replimune Announces Favorable Outcome of FDA's Cellular, Tissue, and Gene Therapies Advisory Committee Meeting for RP1 in Advanced Melanoma
From Replimune, Inc.
Via GlobeNewswire
Tickers REPL
News headline image
Replimune Reports Fiscal Fourth Quarter and Year End 2026 Financial Results and Provides Corporate Update
From Replimune, Inc.
Via GlobeNewswire
Tickers REPL
News headline image
Replimune Announces FDA Acceptance of RP1 Biologics License Application Resubmission for Advanced Melanoma
From Replimune, Inc.
Via GlobeNewswire
Tickers REPL
News headline image
Replimune Presents Final First-in-Human Data for RP2 in Advanced Solid Tumors During Oral Presentation at the 2026 American Society of Clinical Oncology Annual Meeting
From Replimune, Inc.
Via GlobeNewswire
Tickers REPL
News headline image
Replimune Presents 3-Year Landmark Overall Survival Analysis from IGNYTE Clinical Trial During Oral Presentation at the 2026 American Society of Clinical Oncology Annual Meeting
From Replimune, Inc.
Via GlobeNewswire
Tickers REPL
News headline image
Replimune Announces Planned RP1 BLA Resubmission Following Productive Discussion with FDA
From Replimune, Inc.
Via GlobeNewswire
Tickers REPL
News headline image
Replimune to Present at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting
From Replimune, Inc.
Via GlobeNewswire
Tickers REPL
News headline image
Replimune Receives Complete Response Letter from the FDA for RP1 Biologics License Application for the Treatment of Advanced Melanoma
From Replimune, Inc.
Via GlobeNewswire
Tickers REPL
News headline image
Replimune to Present at Two Upcoming Investor Conferences
From Replimune, Inc.
Via GlobeNewswire
Tickers REPL
News headline image
Replimune Reports Fiscal Third Quarter 2026 Financial Results and Provides Corporate Update
From Replimune, Inc.
Via GlobeNewswire
Tickers REPL
News headline image
Replimune to Present at the 44th Annual J.P. Morgan Healthcare Conference
From Replimune, Inc.
Via GlobeNewswire
Tickers REPL
News headline image
Replimune Presents Late-Breaking Abstract and Additional Posters on RP1 at 40th Annual Meeting of the Society for the Immunotherapy of Cancer (SITC 2025)
From Replimune, Inc.
Via GlobeNewswire
Tickers REPL
News headline image
Replimune Reports Fiscal Second Quarter 2026 Financial Results and Provides Corporate Update
From Replimune, Inc.
Via GlobeNewswire
Tickers REPL
News headline image
Replimune Announces FDA Acceptance of BLA Resubmission of RP1 for the Treatment of Advanced Melanoma
From Replimune, Inc.
Via GlobeNewswire
Tickers REPL
News headline image
Replimune Highlights Acral Melanoma Data for RP1 plus Nivolumab at the ESMO Congress 2025
From Replimune, Inc.
Via GlobeNewswire
Tickers REPL
News headline image
Replimune Provides Update Following Type A Meeting with FDA
From Replimune, Inc.
Via GlobeNewswire
Tickers REPL
News headline image
Replimune Announces Type A Meeting Scheduled with FDA
From Replimune, Inc.
Via GlobeNewswire
Tickers REPL
News headline image
Replimune Reports Fiscal First Quarter 2026 Financial Results and Provides Corporate Update
From Replimune, Inc.
Via GlobeNewswire
Tickers REPL
News headline image
Replimune Receives Complete Response Letter from FDA for RP1 Biologics License Application for the Treatment of Advanced Melanoma
From Replimune, Inc.
Via GlobeNewswire
Tickers REPL
News headline image
Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Replimune, Inc.
Via GlobeNewswire
Tickers REPL